By the same authors

From the same journal

Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals

Research output: Contribution to journalArticle

Standard

Prevention of progression to cirrhosis in hepatitis C with fibrosis : effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals. / Faria, R.; Woods, B.; Griffin, S.; Palmer, S.; Sculpher, M.; Ryder, S. D.

In: Alimentary pharmacology & therapeutics, Vol. 44, No. 8, 16.09.2016, p. 866-876.

Research output: Contribution to journalArticle

Harvard

Faria, R, Woods, B, Griffin, S, Palmer, S, Sculpher, M & Ryder, SD 2016, 'Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals', Alimentary pharmacology & therapeutics, vol. 44, no. 8, pp. 866-876. https://doi.org/10.1111/apt.13775

APA

Faria, R., Woods, B., Griffin, S., Palmer, S., Sculpher, M., & Ryder, S. D. (2016). Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals. Alimentary pharmacology & therapeutics, 44(8), 866-876. https://doi.org/10.1111/apt.13775

Vancouver

Faria R, Woods B, Griffin S, Palmer S, Sculpher M, Ryder SD. Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals. Alimentary pharmacology & therapeutics. 2016 Sep 16;44(8):866-876. https://doi.org/10.1111/apt.13775

Author

Faria, R. ; Woods, B. ; Griffin, S. ; Palmer, S. ; Sculpher, M. ; Ryder, S. D. / Prevention of progression to cirrhosis in hepatitis C with fibrosis : effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals. In: Alimentary pharmacology & therapeutics. 2016 ; Vol. 44, No. 8. pp. 866-876.

Bibtex - Download

@article{9b2b30afd40f4f37904af060a511ad99,
title = "Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals",
abstract = "BACKGROUND:The new direct-acting anti-virals (DAAs) for hepatitis C virus (HCV) infection offer higher cure rates, but at a much higher cost than the standard interferon-based treatments.AIM:To identify the cost-effective treatment for patients with HCV infection with F3 liver fibrosis who are at high risk of progression to cirrhosis.METHODS:A decision-analytic Markov model compared the health benefits and costs of all currently licensed treatments as single treatments and in sequential therapy of up to three lines. Costs were expressed in pound sterling from the perspective of the UK National Health Service. Health benefits were expressed in quality-adjusted life years.RESULTS:Treatment before progression to cirrhosis always offers the most health benefits for the least costs. Sequential therapy with multiple treatment lines cures over 89{\%} of patients across all HCV genotypes while ensuring a cost-effective use of resources. Cost-effective regimes for HCV genotype 1 patients include first-line oral therapy with sofosbuvir-ledipasvir while peginterferon continues to have a role in other genotypes.CONCLUSIONS:The cost-effective treatment for HCV can be established using decision analytic modelling comparing single and sequential therapies. Sequential therapy with DAAs is effective and cost-effective in HCV patients with F3 fibrosis. This information is of significant benefit to health care providers with budget limitations and provides a sound scientific basis for drug treatment choices.",
author = "R. Faria and B. Woods and S. Griffin and S. Palmer and M. Sculpher and Ryder, {S. D.}",
note = "{\circledC} 2016, John Wiley & Sons Ltd. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details.",
year = "2016",
month = "9",
day = "16",
doi = "10.1111/apt.13775",
language = "English",
volume = "44",
pages = "866--876",
journal = "Alimentary pharmacology & therapeutics",
issn = "1365-2036",
number = "8",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Prevention of progression to cirrhosis in hepatitis C with fibrosis

T2 - Alimentary pharmacology & therapeutics

AU - Faria, R.

AU - Woods, B.

AU - Griffin, S.

AU - Palmer, S.

AU - Sculpher, M.

AU - Ryder, S. D.

N1 - © 2016, John Wiley & Sons Ltd. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details.

PY - 2016/9/16

Y1 - 2016/9/16

N2 - BACKGROUND:The new direct-acting anti-virals (DAAs) for hepatitis C virus (HCV) infection offer higher cure rates, but at a much higher cost than the standard interferon-based treatments.AIM:To identify the cost-effective treatment for patients with HCV infection with F3 liver fibrosis who are at high risk of progression to cirrhosis.METHODS:A decision-analytic Markov model compared the health benefits and costs of all currently licensed treatments as single treatments and in sequential therapy of up to three lines. Costs were expressed in pound sterling from the perspective of the UK National Health Service. Health benefits were expressed in quality-adjusted life years.RESULTS:Treatment before progression to cirrhosis always offers the most health benefits for the least costs. Sequential therapy with multiple treatment lines cures over 89% of patients across all HCV genotypes while ensuring a cost-effective use of resources. Cost-effective regimes for HCV genotype 1 patients include first-line oral therapy with sofosbuvir-ledipasvir while peginterferon continues to have a role in other genotypes.CONCLUSIONS:The cost-effective treatment for HCV can be established using decision analytic modelling comparing single and sequential therapies. Sequential therapy with DAAs is effective and cost-effective in HCV patients with F3 fibrosis. This information is of significant benefit to health care providers with budget limitations and provides a sound scientific basis for drug treatment choices.

AB - BACKGROUND:The new direct-acting anti-virals (DAAs) for hepatitis C virus (HCV) infection offer higher cure rates, but at a much higher cost than the standard interferon-based treatments.AIM:To identify the cost-effective treatment for patients with HCV infection with F3 liver fibrosis who are at high risk of progression to cirrhosis.METHODS:A decision-analytic Markov model compared the health benefits and costs of all currently licensed treatments as single treatments and in sequential therapy of up to three lines. Costs were expressed in pound sterling from the perspective of the UK National Health Service. Health benefits were expressed in quality-adjusted life years.RESULTS:Treatment before progression to cirrhosis always offers the most health benefits for the least costs. Sequential therapy with multiple treatment lines cures over 89% of patients across all HCV genotypes while ensuring a cost-effective use of resources. Cost-effective regimes for HCV genotype 1 patients include first-line oral therapy with sofosbuvir-ledipasvir while peginterferon continues to have a role in other genotypes.CONCLUSIONS:The cost-effective treatment for HCV can be established using decision analytic modelling comparing single and sequential therapies. Sequential therapy with DAAs is effective and cost-effective in HCV patients with F3 fibrosis. This information is of significant benefit to health care providers with budget limitations and provides a sound scientific basis for drug treatment choices.

U2 - 10.1111/apt.13775

DO - 10.1111/apt.13775

M3 - Article

VL - 44

SP - 866

EP - 876

JO - Alimentary pharmacology & therapeutics

JF - Alimentary pharmacology & therapeutics

SN - 1365-2036

IS - 8

ER -